Dashboard
Manage Tickers

ENTX Entera Bio Ltd.

Nasdaq enterabio.com


$ 2.91 $ 0.12 (4.3 %)    

Wednesday, 05-Nov-2025 13:19:15 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 625.51 $ 7.06 (1.14 %)
DIA $ 473.74 $ 2.87 (0.61 %)
SPY $ 680.40 $ 5.36 (0.79 %)
TLT $ 89.04 $ -0.47 (-0.53 %)
GLD $ 366.45 $ -0.01 (-0 %)
$ 2.8
$ 2.90
$ 2.90 x 1,000
$ 2.93 x 400
$ 2.89 - $ 2.94
$ 1.50 - $ 2.97
266,466
na
131.14M
$ 1.52
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 03-28-2025 12-31-2024 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 03-08-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-05-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-08-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

entera-bio-presents-new-clinical-data-from-phase-2-study-of-eb613-at-2025-north-american-menopause-society-annual-meeting-intends-to-initiate-global-registrational-phase-3-trial-after-july-2025-fda-concurrence
Entera Bio Presents New Clinical Data From...
10/23/2025 13:05:22

Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported ne...

entera-bio-releases-new-phase-2-data-at-nams-2025-showing-that-eb613-an-oral-pth1-34-therapy-consistently-increased-bone-mineral-density-in-both-early-postmenopausal-women-and-those-10-years-post-menopause
Entera Bio Releases New Phase 2 Data At NA...
10/23/2025 12:58:13

Consistency of BMD gains presented at NAMS 2025 demonstrate EB613's efficacy in both young postmenopausal women and in wome...

entera-bio-announces-it-will-present-new-phase-2-clinical-data-for-eb613-at-the-north-american-menopause-society-2025-annual-meeting-october-2125-2025-in-orlando-florida
Entera Bio Announces It Will Present New P...
10/16/2025 12:47:45

Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today announced t...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
10/15/2025 12:09:47

entera-bio-presents-preclinical-data-for-opk-8801003-oral-glp-2-tablet-with-longer-half-life-aiming-to-replace-daily-injections-for-short-bowel-syndrome-patients
Entera Bio Presents Preclinical Data For O...
09/15/2025 13:05:56

Preclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Ga...

entera-bio-to-present-eb613-phase-2-data-at-asbmr-2025-oral-anabolic-tablet-advances-toward-phase-3
Entera Bio To Present EB613 Phase 2 Data A...
09/08/2025 12:33:16

EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Ph...

entera-bio-q2-eps-006-misses-121-estimate
Entera Bio Q2 EPS $(0.06) Misses $1.21 Est...
08/08/2025 20:10:04

Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $1.21 by...

entera-bio-receives-fda-agreement-to-support-eb613-nda-filing-with-single-24-month-global-phase-3-study-in-postmenopausal-osteoporosis-using-total-hip-bmd-as-primary-endpoint-and-vertebral-fracture-incidence-as-key-secondary
Entera Bio Receives FDA Agreement To Suppo...
07/28/2025 11:32:25

Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today ...

Core News & Articles
OPKO Health And Entera Bio To Present Abst...
07/08/2025 12:09:42

entera-bio-selected-to-present-data-for-eb613-effects-on-trabecular-and-cortical-bone-in-post-menopausal-women-with-osteoporosis-at-asbmr-2025-annual-meeting
Entera Bio Selected To Present Data For EB...
06/26/2025 12:10:49

Core News & Articles
OPKO Health And Entera Bio Say New Pharmac...
06/25/2025 12:12:35

OPKO Health, Inc. (NASDAQ:OPK) and Entera Bio Ltd. (NASDAQ:ENTX) ("Entera") today announced that new pharmacologic and ...

entera-bio-q1-eps-006-beats-007-estimate-sales-4200k
Entera Bio Q1 EPS $(0.06) Beats $(0.07) Es...
05/09/2025 20:09:52

Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by...

entera-bio-announces-eb613-impact-on-both-trabecular-and-cortical-bone-compartments-with-6-months-of-treatment-in-post-menopausal-women-with-osteoporosis
Entera Bio Announces EB613 Impact On Both ...
04/15/2025 12:37:43

entera-bio-fy-2024-gaap-eps-025-sales-181000k-beat-139000k-estimate
Entera Bio FY 2024 GAAP EPS $(0.25), Sales...
03/28/2025 20:09:56

Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.25) per share. The company reported quarterly sales of $181.000 thou...

hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Ente...
03/18/2025 15:47:53

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

Core News & Articles
OPKO Health And Entera Bio Enter Collabora...
03/17/2025 12:02:13

entera-bios-eb613-abstracts-for-osteoporosis-treatment-accepted-for-wco-iof-esceo-congress-from-april-10-13-2025-phase-2-shows-rapid-bmd-increase-enhanced-bone-formation-resorption-suppression
Entera Bio's EB613 Abstracts For Osteoporo...
02/19/2025 13:04:00

Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of oral peptide and prot...

hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Ente...
11/11/2024 11:57:52

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

entera-bio-q3-2024-gaap-eps-008-misses-006-estimate-sales-4200k-beat-4000k-estimate
Entera Bio Q3 2024 GAAP EPS $(0.08) Misses...
11/08/2024 21:10:45

Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) ...

hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Ente...
10/07/2024 10:31:00

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION